PROK
PROKIDNEY CORP.
$1.71
-5.00%
$504.4M
No data for this timeframe.
Vol
Market Cap$504.4M
Cap SizeSmall Cap
Analyst ConsensusBuy (67%)
Inst. Holders8 funds
Inst. Value$29.5M
Inst. Activity3 buys / 0 sells
SEC Reports3
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. E9·CIK 0001850270·Prev Close $1.80
Recent Activity
Jun 5, 2026
short_volume
Short Volume: PROK — 77.7% short (0.6M / 0.8M)
Short: 617,217 | Exempt: 0 | TRF Vol: 794,776 | Short Ratio: 77.7% | Off-exchange volume (dark pool
May 28, 2026
Insider
Pereira Brian JG sold 135,000 shares
Director @ $0.00 ($0.00)
May 28, 2026
Insider
Legorreta Pablo G. sold 135,000 shares
Director @ $0.00 ($0.00)
May 28, 2026
Insider
Sinha Uma sold 135,000 shares
Director @ $0.00 ($0.00)
May 15, 2026
SEC
ProKidney reported Q1 2026 financial results that were in line with consensus, with a net loss of $20.0M available to Cl
8-K — Impact 4/10
May 15, 2026
SEC
ProKidney reported Q1 2026 EPS of -$0.14, essentially in line with the -$0.14 consensus (a 1.8% miss), with negligible r
PRESS-RELEASE — Impact 5/10
Apr 17, 2026
SEC
ProKidney Corp. filed a definitive proxy statement (DEFA14A) for its upcoming shareholder meeting. The filing is routine
DEFA14A — Impact 2/10
Inst.
MORGAN STANLEY — ADD
8,817,001 shares ($19.8M)
Price Targets
$6.25
+274.3% upside
Strong Buy
Current $1.67
Low $1.00
Median $5.75
High $12.00
6 analysts
$1.00
$12.00
Analyst Ratings
5Strong Buy
5Buy
4Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Dec 16, 2025 | HC Wainwright & Co. | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.14 ▲ +3.7% | $-0.16 — $-0.11 | -6% YoY | 5 |
| Next Q | $-0.14 ▲ +8.1% | $-0.17 — $-0.12 | -18% YoY | 5 |
| Current FY | $-0.54 ▲ +23.1% | $-0.65 — $-0.49 | -4% YoY | 5 |
| Next FY | $-0.58 ▲ +21.0% | $-0.83 — $-0.40 | -7% YoY | 5 |
Latest Reports
NEUTRAL
8-K
4/10
ProKidney reported Q1 2026 financial results that were in line with consensus, with a net loss of $20.0M available to Cl
May 15, 2026
NEUTRAL
PRESS-RELEASE
5/10
ProKidney reported Q1 2026 EPS of -$0.14, essentially in line with the -$0.14 consensus (a 1.8% miss), with negligible r
May 15, 2026
MIXED
Press
6/10
ProKidney reported financial results for 2025, highlighting a reduction in net loss to $151.6 million from $163.3 millio
Mar 18, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $19.8M | ADD |
| VANGUARD GROUP INC | $3.7M | NEW |
| RENAISSANCE TECHNOLOGIES LLC | $2.0M | DOUBLED |
| BANK OF AMERICA CORP | $1.6M | NEW |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $1.4M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 28, 2026 | Pereira Brian | A | $0.00 |
| May 28, 2026 | Legorreta Pablo | A | $0.00 |
| May 28, 2026 | Sinha Uma | A | $0.00 |
| May 28, 2026 | Lotvin Alan | A | $0.00 |
| May 28, 2026 | Jimenez Santos | A | $0.00 |
8 institutional holders with $29.5M total value (13,169,008 shares) as of 2025-Q4. Top holders: MORGAN, VANGUARD, RENAISSANCE. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 8,817,001 | $19.8M | 67.0% | ADD +30.7% |
| 2 | VANGUARD GROUP INC | 1,648,229 | $3.7M | 12.5% | NEW |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 895,705 | $2.0M | 6.8% | DOUBLED +578.6% |
| 4 | BANK OF AMERICA CORP /DE/ | 706,144 | $1.6M | 5.4% | NEW |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 623,110 | $1.4M | 4.7% | NEW |
| 6 | TWO SIGMA INVESTMENTS, LP | 465,509 | $1.0M | 3.5% | DOUBLED +368.9% |
| 7 | FMR LLC | 10,310 | $23.1K | 0.1% | NEW |
| 8 | WELLS FARGO & COMPANY/MN | 3,000 | $6.7K | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 6,747,022 | 8,817,001 | +30.7% | $19.8M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 132,000 | 895,705 | +578.6% | $2.0M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 99,282 | 465,509 | +368.9% | $1.0M | 2025-Q4 |
| MORGAN STANLEY | NEW | — | 6,747,022 | — | $16.3M | 2025-Q3 |
| VANGUARD GROUP INC | NEW | — | 1,564,116 | — | $3.8M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEW | — | 660,864 | — | $1.6M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 653,091 | — | $1.6M | 2025-Q3 |
| UBS Group AG | NEW | — | 508,353 | — | $1.2M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 132,000 | — | $319.4K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 99,282 | — | $240.3K | 2025-Q3 |
| FMR LLC | NEW | — | 11,901 | — | $28.8K | 2025-Q3 |
12 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 28, 2026 | Pereira Brian JG | Director | A | 135,000 | $0.00 | $0.00 |
| May 28, 2026 | Legorreta Pablo G. | Director | A | 135,000 | $0.00 | $0.00 |
| May 28, 2026 | Sinha Uma | Director | A | 135,000 | $0.00 | $0.00 |
| May 28, 2026 | Lotvin Alan | Director | A | 135,000 | $0.00 | $0.00 |
| May 28, 2026 | Jimenez Santos Jose Ignacio | Director | A | 135,000 | $0.00 | $0.00 |
| May 28, 2026 | DOYLE WILLIAM F | Director | A | 135,000 | $0.00 | $0.00 |
| May 28, 2026 | Fox Jennifer A. | Director | A | 135,000 | $0.00 | $0.00 |
| Apr 28, 2026 | Control Empresarial de Capitales S.A. de C.V. | 10%+ Owner | C | 63,118,645 | $0.00 | $0.00 |
| Apr 28, 2026 | Control Empresarial de Capitales S.A. de C.V. | 10%+ Owner | C | 63,118,645 | $0.00 | $0.00 |
| Apr 28, 2026 | Control Empresarial de Capitales S.A. de C.V. | 10%+ Owner | C | 63,118,645 | $0.00 | $0.00 |
| Mar 1, 2026 | Coulston James | Chief Financial Officer | A | 600,000 | $0.00 | $0.00 |
| Mar 1, 2026 | Weber Darin J. | Chief Regulatory Officer | A | 400,000 | $0.00 | $0.00 |
| Mar 1, 2026 | Girolamo Todd C | Chief Legal Officer | A | 600,000 | $0.00 | $0.00 |
| Mar 1, 2026 | Culleton Bruce | Chief Executive Officer | A | 3,000,000 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 3.7/10.
NEUTRAL
8-K
4/10
ProKidney reported Q1 2026 financial results that were in line with consensus, with a net loss of $2
May 15, 2026
NEUTRAL
PRESS-RELEASE
5/10
ProKidney reported Q1 2026 EPS of -$0.14, essentially in line with the -$0.14 consensus (a 1.8% miss
May 15, 2026
NEUTRAL
DEFA14A
2/10
ProKidney Corp. filed a definitive proxy statement (DEFA14A) for its upcoming shareholder meeting. T
Apr 17, 2026
Current analyst consensus: Buy (67% buy). Based on 15 analysts: 5 strong buy, 5 buy, 4 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$6.25 mean target
+274.3% upside
Strong Buy (2.00)
$1.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $1.67 |
| Target Low | $1.00 |
| Target Mean | $6.25 |
| Target Median | $5.75 |
| Target High | $12.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (2.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.14 | $-0.16 | $-0.11 | -6.2% | +3.7% | 3↑ 1↓ | $0.0B | -32.6% | 5 |
| Next Q 2026-09-30 |
$-0.14 | $-0.17 | $-0.12 | -17.8% | +8.1% | 3↑ 0↓ | $0.0B | -42.0% | 5 |
| Current FY 2026-12-31 |
$-0.54 | $-0.65 | $-0.49 | -3.5% | +23.1% | 5↑ 0↓ | $0.0B | -42.8% | 5 |
| Next FY 2027-12-31 |
$-0.58 | $-0.83 | $-0.40 | -7.1% | +21.0% | 3↑ 1↓ | $0.0B | -12.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.138 | |
| 7d ago | $-0.143 | +0.005 |
| 30d ago | $-0.143 | +0.005 |
| 60d ago | $-0.143 | +0.005 |
| 90d ago | $-0.170 | +0.032 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 16, 2025 | HC Wainwright & Co. | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 5 | 4 | 1 | 0 | 67% | |
| May 1, 2026 | 5 | 5 | 4 | 1 | 0 | 67% | |
| Apr 1, 2026 | 5 | 5 | 4 | 1 | 0 | 67% | |
| Mar 1, 2026 | 5 | 5 | 4 | 1 | 0 | 67% | |
| Feb 1, 2026 | 5 | 5 | 4 | 1 | 0 | 67% | |
| Jan 1, 2026 | 5 | 5 | 4 | 1 | 0 | 67% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 5, 2026
short_volume
Short Volume: PROK — 77.7% short (0.6M / 0.8M)
Short: 617,217 | Exempt: 0 | TRF Vol: 794,776 | Short Ratio: 77.7% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
other
ProKidney Appoints Kenneth Locke as Chief Technical Officer
Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Suppl
Jun 2, 2026
short_volume
Short Volume: PROK — 56.8% short (0.4M / 0.8M)
Short: 437,942 | Exempt: 14,037 | TRF Vol: 770,698 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: PROK — 57.7% short (0.3M / 0.5M)
Short: 294,979 | Exempt: 6,001 | TRF Vol: 511,100 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
May 15, 2026
earnings
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
<p align="justify">WINSTON-SALEM, N.C., May 15, 2026 (GLOBE NEWSWIRE) -- <strong>ProKidney Corp. (Nasdaq: PROK) </strong>(“ProKidney” or the “Compan
May 13, 2026
earnings_calendar
PROK Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings_calendar
PROK Q1 2026 Earnings Scheduled — 2026-05-11
May 11, 2026
short_volume
Short Volume: PROK — 55.4% short (0.3M / 0.6M)
Short: 342,964 | Exempt: 5,055 | TRF Vol: 618,830 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: PROK — 68.9% short (0.3M / 0.5M)
Short: 347,162 | Exempt: 5,000 | TRF Vol: 503,962 | Short Ratio: 68.9% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
short_volume
Short Volume: PROK — 77.3% short (1.3M / 1.7M)
Short: 1,285,953 | Exempt: 41,530 | TRF Vol: 1,663,201 | Short Ratio: 77.3% | Off-exchange volume (dark pool + OTC)
Apr 2, 2026
short_volume
Short Volume: PROK — 79.1% short (0.4M / 0.5M)
Short: 423,437 | Exempt: 200 | TRF Vol: 535,415 | Short Ratio: 79.1% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
short_volume
Short Volume: PROK — 57.9% short (0.3M / 0.5M)
Short: 318,265 | Exempt: 24,500 | TRF Vol: 549,544 | Short Ratio: 57.9% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
short_volume
Short Volume: PROK — 77.2% short (0.6M / 0.8M)
Short: 600,471 | Exempt: 6,740 | TRF Vol: 777,714 | Short Ratio: 77.2% | Off-exchange volume (dark pool + OTC)
Mar 25, 2026
other
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
Veteran commercial executive brings deep nephrology and specialty biopharma leadership experience as ProKidney advances rilparencel toward potential c
Mar 24, 2026
short_volume
Short Volume: PROK — 76.4% short (0.4M / 0.6M)
Short: 448,962 | Exempt: 8,393 | TRF Vol: 587,439 | Short Ratio: 76.4% | Off-exchange volume (dark pool + OTC)